Status:

COMPLETED

Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy

Lead Sponsor:

Alcon Research

Conditions:

Glaucoma

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.

Eligibility Criteria

Inclusion

  • Adults with a clinical diagnosis of ocular hypertension, or primary open-angle, pigment dispersion or exfoliation glaucoma in at least one eye (study eye)

Exclusion

  • Age

Key Trial Info

Start Date :

May 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2007

Estimated Enrollment :

750 Patients enrolled

Trial Details

Trial ID

NCT00444665

Start Date

May 1 2007

End Date

August 1 2007

Last Update

November 21 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fridley

Fridley, Minnesota, United States, 55432

Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy | DecenTrialz